2025 drug reimbursement trends report

We're thrilled to publish our very first Drug Reimbursement Trends Report in joint authorship with ZS. Read more about the report below or skip to good stuff and 👉 download the report here.

Turquoise Health and ZS’s 2025 Drug Reimbursement Trends Report

In partnership with ZS, the report analyzes millions of hospital and payer reported drug rates to identify cross-therapeutic area trends. Examining seventeen medical benefit products across four high-cost therapeutic areas, the report reveals the extent to which drug reimbursement is influenced by local payer–provider control and contracting dynamics.

Findings indicate that while many providers are reimbursed near Average Sales Price (ASP), hospitals, especially under commercial contracts, frequently secure rates 3–5× ASP, with outliers hitting 10× ASP for some biosimilars. The report highlights the reimbursement insights that can be extracted at the individual payer, provider, and product level through Transparency in Coverage (TiC) data.

Key takeaways in the report

• Payer-provider reimbursement is heavily influenced by provider-payer control dynamics across therapeutic areas.
• Hospitals are ~3× more likely than Specialty Groups to secure premium rates above 200% of ASP, fueling large differences in the costs of products & services across sites-of-care and across individual providers.
• Regional payers are more exposed to higher reimbursement rates than national payers, reflecting local providers’ stronger bargaining power
• Reimbursement differences across products carry significant revenue implications for providers; there’s evidence these implications can be as high as $100k per patient per year.
• With Price Transparency, knowledge is power. These insights give us an early peek into a future world where healthcare is more shoppable, where patients have more power, and where transparency amplifies competition and puts downward pressure on healthcare costs..

These hidden price variations shape prescribing incentives across healthcare. As policymakers revisit stalled transparency rules, including the Prescription Drug file under Transparency in Coverage (TiC), pharmaceutical leaders have an opportunity to put reimbursement insights into the hands of patients to improve access and affordability, while simultaneously optimizing gross-to-net through more precise pricing and contracting strategies. 👉 Download the report here